Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 17/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689125 | 0.90 | PIM1 (0.41) | PIM1PIM3PIM2DGAT1 | |
| SCHEMBL19750544 | 0.89 | PIM1 (0.49) | PIM1PIM3PIM2MAPT | |
| SCHEMBL14688870 | 0.88 | PIM1 (0.53) | PIM1PIM3PIM2DGAT1MAPT | |
| SCHEMBL14688571 | 0.88 | PIM1 (0.42) | PIM1PIM3PIM2DGAT1MAPT | |
| SCHEMBL14688765 | 0.87 | PIM1 (0.42) | PIM1PIM3PIM2DGAT1MAPT | |
| SCHEMBL14689076 | 0.86 | PIM1 (0.38) | PIM1PIM3PIM2DGAT1MAPT | |
| SCHEMBL14688835 | 0.85 | PIM1 (0.52) | PIM1PIM3PIM2DGAT1MAPT | |
| SCHEMBL14688516 | 0.85 | PIM1 (0.49) | PIM1PIM3PIM2DGAT1MAPT | |
| SCHEMBL14713858 | 0.82 | CYP2A6 (0.41) | PIM1PIM3PIM2DGAT1MAPT | |
| SCHEMBL14688761 | 0.81 | DGAT1 (0.40) | PIM1PIM3PIM2DGAT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850239-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENENTECH, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850239-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENENTECH, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850239-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENENTECH, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9260425-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENETECH, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2742046-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013024002-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | PIM1 1/4885PIM3 2/4885PIM2 3/4885 |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | PIM1 1/4885PIM3 2/4885PIM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.